Five firms will guide initial public offerings projected to surpass $3.9 billion during the week of May 7, led by Axa Equitable Holdings Inc., the U.S. division of French insurance and asset management firm Axa SA, which could price the biggest U.S. IPO since 2014.
The Federal Circuit on Friday reopened a proceeding to determine whether The General Hospital Corp. or Sienna Biopharmaceuticals Inc. was the first to invent a hair removal method, vacating part of a ruling from the Patent Trial and Appeal Board.
Two men charged with defrauding Valeant Pharmaceuticals International Inc. out of $9.7 million when it moved to buy Philidor Rx Services LLC sought on Friday to rebut claims they hid anything from Valeant at trial, pressing Valeant’s chief compliance officer about her duties and the links between the two companies.
Loeb & Loeb LLP counsel Eve Costopoulos sued Martin Shkreli on Thursday, claiming in Manhattan federal court that the pharma fraudster targeted her with a campaign of "character assassination" at her previous job as Turing Pharmaceuticals LLC general counsel, as she dealt with fallout from his famed AIDS drug price hike.
A Pennsylvania federal judge on Friday agreed to allow an injured child's parents to amend a complaint accusing Flaherty Fardo PC of missing the window for a medical malpractice case to clarify whether they had waived their otherwise unexpired right to seek medical expenses on the boy's behalf.
Mylan Pharmaceuticals Inc. and a pair of chemical companies on Thursday settled with a Blue Cross Blue Shield affiliate, coming closer to ending their appeal of a $67 million verdict that found they fixed the price of anti-anxiety medications.
A doctor who helped design allegedly defective metal-on-metal hip replacements at issue in multidistrict litigation against Biomet escaped a suit Thursday in Indiana federal court on jurisdictional grounds.
Shares of venture-backed startup Carbon Black Inc. rallied Friday after the cybersecurity software firm raised $152 million in an initial public offering that priced at the top of its upwardly revised range, capping a week that saw eight IPOs raise a total of $733 million.
Perkins Coie LLP said it has hired a former DLA Piper partner who has represented startups and technology clients in the health care, e-commerce, biotech and renewable energy industries to head Perkins Coie's emerging companies and venture capital practice in Arizona.
Shire PLC is trying to overbill a generic competitor with a $2.38 million fee request after winning a patent infringement suit over its popular hyperactivity treatment Adderall XR, Shire’s competitor told a Massachusetts federal judge late Thursday.
The city of Los Angeles on Thursday became the latest to accuse top drugmakers and distributors of fueling the nation's opioid epidemic by engaging in deceptive marketing aimed at boosting sales of powerful, addictive painkillers such as OxyContin, methadone and fentanyl.
A solo practitioner and a six-man class action firm sought approval Wednesday to take a $5.65 million slice of a $13.45 million proposed settlement on behalf of a class of doctors with Allergan that resolved allegations the company cut a deal to keep a Botox competitor off the market.
Federal prosecutors fired their opening salvo on Thursday against two former executives of Philidor Rx Services LLC who allegedly ripped off medical giant Valeant Pharmaceuticals International Inc., telling a Manhattan jury that the men extracted a $9.7 million kickback from the company and used shell companies to cover it up.
The U.S. Food and Drug Administration’s leader on Thursday signaled that the Trump administration’s campaign to reduce drug prices will target an Anti-Kickback Statute safe harbor for controversial rebates that drugmakers give to pharmacy benefit managers.
The Patent Trial and Appeal Board rightfully invalidated the bulk of claims in a Four Mile Bay LLC hip implant patent following a challenge from competitor Zimmer Biomet Holdings Inc., the Federal Circuit ruled Thursday.
Fox Rothschild LLP has lured a patent expert and former New York managing partner from Merchant & Gould PC to expand its intellectual property practice.
Public Citizen and the city of Baltimore on Thursday asked the White House to invoke its right to make generic versions of the opioid overdose drug naloxone, as the patented versions are prohibitively expensive for the officials and communities that need them.
A New York pharmacy has urged the Eighth Circuit to revive an antitrust and breach of contract suit accusing Express Scripts of baiting the pharmacy into a mail-order contract only to drop the deal months later, arguing the lower court “made premature factual findings.”
Patent suits involving generic drugs increased 29 percent in 2017 over the previous year, with a hefty 60 percent spike in Delaware, according to a Thursday report by Lex Machina, and attorneys say the Delaware numbers are likely tied to the U.S. Supreme Court’s TC Heartland ruling.
The U.S Department of Commerce’s National Institute of Standards and Technology has outlined a series of changes to the regulation governing patents that stem from federally funded research, the most significant of which will eliminate the time limit on when the feds can demand title to those patents. Here, Law360 looks at what updates IP attorneys should know about.
In order to enable lawyers to best meet cybersecurity challenges, state bars should pass rules that adopt a cybersecurity framework to be developed by a national committee, says Shaun Jamison, associate dean of faculty and professor at Purdue University's Concord Law School.
Medical marijuana programs in New York and New Jersey restrict the number of medical conditions that qualify for cannabis treatment. But both states are moving toward expanding their programs, creating opportunities for patients and businesses alike, say Joshua Bauchner and Anthony D'Artiglio of Ansell Grimm & Aaron PC.
To many young attorneys, becoming an equity partner shows a firm's long-term commitment, meaning job security and a voice in important firm matters. However, the industry has changed and nowadays it may not be better to enter a new firm as an equity partner, says Jeffrey Liebster of Major Lindsey & Africa.
As illustrated by the Federal Circuit's recent decision in Exergen v. Kaz, not every diagnosis patent is invalid for being directed to a law of nature. An analysis of the majority and dissenting opinions, as well as the way the claims at issue were worded, will hopefully shed light on the types of claims that will survive eligibility challenges, says Matthew Siegal of Dilworth & Barrese LLP.
While the lists of conditions for which medical marijuana is available in various states have expanded, and while the number of states in which marijuana use is authorized has also increased, such developments have not made it easier for college students to use marijuana on campuses, say attorneys with Saul Ewing Arnstein & Lehr LLP.
In his new book, "Without Precedent: Chief Justice John Marshall and His Times," professor Joel Richard Paul ably explains more than a dozen of Marshall’s most significant opinions, which comes as no surprise. What is a surprise — a pleasant one — is the book's readability, says Judge Thomas Hardiman of the Third Circuit.
For law firms structured as corporations, a lower maximum corporate tax rate and repeal of the corporate alternative minimum tax are good news. But many law firms are pass-through entities, so deduction limitations mean they'll see less benefit from the new tax law, says Evan Morgan of CPA and advisory firm Kaufman Rossin PA.
A California federal court's recent decision in National Association of Wheat Growers v. Zeise, which blocked the state from requiring Monsanto to put Proposition 65 warning labels on its Roundup products, may seem surprising at first blush. But a deeper look at the broader historical context of Proposition 65 offers a different perspective, say Shannon Oldenburg and Malcolm Weiss of Hunton & Williams LLP.
With three decisions last month, the ethereal world of patent subject matter eligibility is getting even murkier. As jurists and practitioners try to work through the confusion created by the U.S. Supreme Court's untenable Alice test, the U.S. patent community is suffering, says Robert Stoll, a partner at Drinker Biddle & Reath LLP and former commissioner for patents.
With new leadership poised to take the helm at the Federal Trade Commission, now is an opportune time to review the latest consumer protection trends and developments, say attorneys with Cooley LLP.